Axsome Therapeutics (NASDAQ:AXSM) has received mixed analyst ratings over the past three months, with 6 analysts offering opinions ranging from bullish to bearish. The average 12-month price target for AXSM is $135.67, with a high estimate of $180.00 and a low of $108.00, indicating a 50.74% increase from the previous average target of $90.00. Analysts from firms including Piper Sandler, HC Wainwright & Co., Cantor Fitzgerald, and Citigroup have provided updates, with one raising the price target from $90.00 to $113.00. Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on CNS disorders. Financially, the company has shown a significant revenue growth rate of 243.07% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -107.62%, ROE of -22.69%, and ROA of -10.26%. Its debt-to-equity ratio of 0.69 is below the industry average.